Publications by authors named "Kevin Reverse"

Claim this Profile
I
Identification of unknown impurities J, RRT 2.2, 2.4, 2.6 and 3.4 in tetralysal® capsules.
Stéphan Billié, Kevin Reversé, Jean-Marie Arlabosse, Didier Bertin, Antoine Boulier

Eur J Pharm Sci· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete H, C, and N assignments of the minor isomer of codeine N-oxide.
Jean-Guy Boiteau, Gregoire Mouis, Kevin Reverse, Estelle Surget, Gaetan Boccadifuoco

Magn Reson Chem· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Completion of the impurity profile of lymecycline: Formal identification of impurities E and F.
Stéphan Billié, Kevin Reversé, Sandrine Chambon, Tony Cachot, Romain Pierre

J Pharm Biomed Anal· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne.
Jean-François Fournier, Laurence Clary, Sandrine Chambon, Laurence Dumais, Craig Steven Harris, Kevin Reverse

J Med Chem· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.
Jean-Guy Boiteau, Gilles Ouvry, Jean-Marie Arlabosse, Stéphanie Astri, Audrey Beillard

Bioorg Med Chem· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel TACE inhibitors compatible with topical application.
Gilles Ouvry, Yaël Berton, Yushma Bhurruth-Alcor, Laetitia Bonnary, Claire Bouix-Peter

Bioorg Med Chem Lett· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis